Company Reports

CooperCompanies is one of the largest eyecare companies in the US. It operates in two segments: CooperVision and CooperSurgical.

CooperCompanies delivered 1% and 4% revenue and adjusted earnings per share growth, respectively. Full-year guidance for both figures was lowered by a low-single-digit percentage. Shares traded down 17% after hours.

CooperCompanies delivered 8% (5% organic) and 26% revenue and adjusted EPS growth, respectively, during the second fiscal quarter. Both figures landed ahead of FactSet consensus. Shares are trading sideways after hours.

Cooper Companies opened fiscal 2026 with 3% organic revenue growth year over year and adjusted EPS of $1.10, up 20% over the prior-year period. The firm lifted 2026 adjusted EPS guidance to $4.62 at the midpoint, which lands ahead of FactSet consensus expectations of $4.52.

CooperCompanies delivered 4.6% revenue growth and 11% adjusted EPS growth, both ahead of FactSet consensus, during fourth-quarter fiscal 2025. Fiscal 2026 guidance of 4.5%-5.5% organic sales growth and 8%-11% EPS growth is ahead of consensus. Shares rallied 10% after hours.

CooperCompanies is one of the largest eyecare companies in the US. It operates in two segments: CooperVision and CooperSurgical.

Cooper Companies reported third-quarter operating results, including 6% year-over-year revenue growth that was in line with FactSet consensus and 15% adjusted EPS growth that was slightly above consensus.

CooperCompanies is one of the largest eyecare companies in the US. It operates in two segments: CooperVision and CooperSurgical.

CooperCompanies is one of the largest eyecare companies in the US. It operates in two segments: CooperVision and CooperSurgical.

Narrow-moat CooperCompanies reported second-quarter earnings with steady results. Total revenue of $1.0 billion was up 6.3% year over year and came largely in line with our expectations, and adjusted earnings per share landed at $0.96, up 13.6% and a bit ahead of our estimates. Management maintained full-year revenue guidance at the midpoint and raised earnings guidance by a low-single-digit percentage; this is inclusive of tariff pressures, which at current levels are expected to result in a $4 million cost of goods sold headwind, or about a 10 basis point gross margin hit. For next fiscal year, tariffs are expected to be a 3% earnings headwind before mitigation actions.

On April 2, President Donald Trump announced a sweeping set of tariffs on all imports ranging from 10% to varying reciprocal rates, effective on April 5. In response, the broad vision care market opened on April 3 about a mid-single-digit percent down from April 2’s close and firms under our coverage—Alcon, Bausch & Lomb, Carl Zeiss, and Cooper Companies—are all trading at the level or lower at the time of writing.

Narrow-moat CooperCompanies reported first-quarter earnings that were largely in line with our expectations. Total sales of $965 million were up 4% year over year, slightly falling short of market consensus. This appears to have rattled investors, causing shares to drop 5% in after-hours trading. We view this as a minor setback due to channel inventory contraction, but the business has quickly regained momentum, and we continue to expect moderate growth in 2025. Following this quarter’s results, management has reiterated its sales guidance of $4.08 billion-$4.16 billion and raised the lower end of its earnings per share outlook, now forecasting a range of $3.94-$4.02. We maintain our fair value estimate of $90 per share.

Narrow-moat CooperCompanies reported solid fourth-quarter earnings and capped off the fiscal year in a nice fashion. Total sales of $1.0 billion were up 9.8% year over year and came in slightly higher than our estimate. The vision and surgical segments enjoyed a solid performance and delivered 8.6% and 12.4% growth, respectively. Margins also tracked ahead of our expectations and helped beat full-year EPS guidance by low single digits. Despite the good readout, 2025 guidance looks slightly below consensus estimates, with management citing some demand softness at the end of November in regions like the US and China. We think this spooked investors somewhat and sent shares down about 5% after hours, but we see it more as a slight hiccup and still expect moderate growth in 2025. While our assumption of 6% growth is below growth levels over the past four years, we think cooling inflation puts pressure on Cooper over the size of price increases it can make for contact lenses; it expects price rises for these products to contribute about a third of growth. That said, the demand environment still looks favorable and we still expect further lens trade-ups. We maintain our $90 fair value estimate.

Narrow-moat CooperCompanies reported solid third-quarter results that came in slightly ahead of our expectations. Total sales of $1.0 billion were up 7.9% year over year thanks to a broad-based growth across the firm. CooperVision was up 7.3% despite lapping last year’s double-digit growth, and we attribute this to growing demand and solid execution. Capacity constraints continue to ease but demand still looks to be outpacing supply, especially within the MyDay portfolio, and we think resolving this will be a multiquarter workout. CooperSurgical, up 9.1%, continues to impress us with its ability to consistently deliver solid numbers. Against the backdrop of strong performance, Cooper raised its sales guidance about 2% at midpoint driven by an improved outlook in both business units. After updating our model and accounting for time value of money, we raise our fair value estimate to $90 per share from $88.

CooperCompanies is one of the largest eyecare companies in the US. It operates in two segments: CooperVision and CooperSurgical.

CooperCompanies is one of the largest eyecare companies in the US. It operates in two segments: CooperVision and CooperSurgical.

Narrow-moat CooperCompanies reported fiscal second-quarter results above our expectations. Total sales of $943 million were up 7.4% year over year thanks to solid execution across geographies, with every market posting strong organic sales growth. With a backdrop of healthy demand and market outperformance, management raised its full-year guidance for both segments. Its earnings per share outlook is now $3.54-$3.60, up from $3.50-$3.58. After increasing our near-term assumptions and including the time value of money, we've raised our fair value estimate to $88 per share from $86.

The Cooper Companies is one of the largest eye care companies in the U.S. It operates in two segments: CooperVision and CooperSurgical.

Narrow-moat Cooper Companies reported fiscal first-quarter results slightly above our expectations. Total sales were up 8.5% year over year, mainly driven by the strong performance of premium toric and multifocal lenses and contributions from the acquired Cook Medical assets. We maintain our $86 fair value estimate as our model adjustments were not significant enough to change our valuation.

Narrow-moat Cooper Companies announced a 4-for-1 stock split that went into effect after the market closed on Friday, Feb. 16. After updating our model to account for this, we establish a new fair value estimate of $86 per share. We think the stock, which currently trades in a 3-star territory, is fairly valued.